A tumor-specific Th2 clone initiating tumor rejection via primed CD8+ cytotoxic T-lymphocyte activation in mice

Cancer Research

Volumn 56, Issue 21, 1996, Pages 5005-5011

  Shen, Yuan ^a   Fujimoto, Shigeyoshi ^a  

^a KOCHI MEDICAL SCHOOL   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

3 METHYLCHOLANTHRENE; CD8 ANTIGEN;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; CANCER INHIBITION; CELL CLONING; CELL TRANSFER; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; GRAFT REJECTION; MALE; MOLECULAR CLONING; MOUSE; NONHUMAN; PRIORITY JOURNAL; T LYMPHOCYTE ACTIVATION; TUMOR REGRESSION;

ADOPTIVE TRANSFER; ANIMALS; CLONE CELLS; CYTOKINES; LYMPHOCYTE ACTIVATION; MALE; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; NEOPLASMS, EXPERIMENTAL; RATS; T-LYMPHOCYTES, CYTOTOXIC; TH2 CELLS;

EID: 0029952791     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. +,2- T cells Tumor eradication does not require participation of cytotoxic T cells. J Exp Med., 161: 1122-1134, 1985.
2. + T lymphocytes by B7, a natural ligand for CD28, can be used to treat established mouse melanoma. J. Immunol., 153: 421-428, 1994.
3. McBride, W. H., Thacker, J. D., Comora, S., Economou, J. S., Kelley, D., Hogge, D., Dubinett, S. M., and Dougherty, G. J. Genetic modification of a murine fibrosarcoma to produce interleukin 7 stimulates host cell infiltration and tumor immunity Cancer Res., 52: 3931-3937, 1992.
4. + T cell clones specific for the human p97 melanoma-associated antigen can eradicate pulmonary metastases from a murine tumor expressing the p97 antigen. J. Immunol., 146: 3235-3241, 1991.
5. Quentmeier, H., Klaucke, J., Muhlradt, P. F., and Drexler, H. G. Role of IL-6, IL-2, and IL-4 in the in vitro induction of cytotoxic T cells. J Immunol., 149: 3316-3320, 1992.
6. Greenberg, P. D. Adoptive T cell therapy of tumors: mechanisms operative in the recognition and elimination of tumor cells (Review). Adv. Immunol., 49: 281-355, 1991.
7. Kast, W. M., Offringa, R., Peters, P. J., Voordouw, A. C., Meloen, R. H., van der Eb, A., and Melief, C. J. Eradication of adenovirus E1-induced tumors by E1A-specific cytotoxic T lymphocytes. Cell, 59: 603-614, 1989.
8. Toes, R. E., Offringa, R., Blom, R. J., Brandt, R. M., van der Eb, A., Melief, C. J., and Kast, W. M. An adenovinis type 5 early region 1B-encoded CTL epitope-mediating tumor eradication by CTL clones is down-modulated by an activated ras oncogene J Immunol., 154: 3396-3405, 1995.
9. + cells, and the effect of administration of recombinant murine interferon gamma in listerial infection. J Exp. Med., 171: 1141-1154, 1990.
10. + T cell-dependent tumor rejection. J. Exp. Med., 174: 1291-1298, 1991.
11. Tepper, R. I., Pattengale, P. K., and Leder, P. Murine interleukin-4 displays potent anti-tumor activity in vivo Cell, 57: 503-512, 1989.
12. Mosmann, T. R., Cherwinski, H., Bond, M. W., Giedlin, M. A., and Coffman, R. M. Two types of murine helper T cell clone. I. Definition according to profiles of lymphokine activities and secreted proteins J. Immunol., 136: 2348-2357, 1986.
13. Cherwinski, H. M., Schumacher, J. H., Brown, K. D., and Mosmann, T. R. Two types of mouse helper T cell clone. III. Further differences in lymphokine synthesis between Th1 and Th2 clones revealed by RNA hybridization, functionally monospecific bioassays, and monoclonal antibodies. J. Exp. Med., 166: 1229-1244, 1987.
14. Fiorentino, D. F., Bond, M. W., and Mosmann, T. R. Two types of mouse T helper cell. IV Th2 clones secrete a factor that inhibits cytokine production by Th1 clones. J. Exp Med., 170: 2081-2095, 1989.
15. Scott, P., Natovitz, P., Coffman, R. L., Pearce, E., and Sher, A. Immunoregulation of cutaneous leishmaniasis T cell lines that transfer protective immunity or exacerbation belong to different T helper subsets and respond to distinct parasite antigens J Exp. Med., 168: 1675-1684, 1988.
16. Fujimoto, S., Matsuzawa, T., Nakagawa K., and Tada, T. Cellular interaction between cytotoxic and suppressor T cells against syngeneic tumors in the mouse. Cell. Immunol., 38: 378-387, 1978.
17. Maeda, H., Takata, M., Takahashi, S., Ogoshi, S., and Fujimoto, S. Adoptive transfer of a Th2-like cell line prolongs MHC class II antigen disparate skin allograft survival in the mouse. Int. Immunol., 6: 855-862, 1994.
18. Maisuda, T., Hirano, T., and Kishimoto, T. Establishment of an interleukin 6 (IL 6)/B cell stimulatory factor 2-dependent cell line and preparation of anti-IL6 monoclonal antibodies. Eur J Immunol., 18: 951-956, 1988.
19. Schumacher, J. H., O'Garra, A., Shrader, B., van Kimmenade, A., Bond, M. W., Mosmann, T. R., and Coffman, R. L. The characterization of four monoclonal antibodies specific for mouse IL-5 and development of mouse and human IL-5 enzyme-linked immunosorbent J. Immunol., 141: 1576-1581, 1988.
20. Lohoff, M., Sommer, F., and Rollinghoff, M. Suppressive effect of interferon-gamma on the BCL1 cell-dependent interleukin 5 bioassay. Eur. J. Immunol., 19: 1327-1329, 1989.
21. Hogan, M. M., and Vogel, S. N. Production of tumor necrosis factor by rIFN-gamma-primed C3H/HeJ (Lpsd) macrophages requires the presence of lipid A-associated proteins J Immunol., 141: 4196-4202, 1988.
22. Murray, H. W., and Hariprashad, J. Interleukin 12 is effective treatment for an established systemic intracellular infection: experimental visceral leishmaniasis. J. Exp Med., 181: 387-391, 1995.
23. Skeiky, Y. A., Guderian, J. A., Benson, D. R., Bacelar, O., Carvalho, E. M., Kubin, M., Badaro, R., Trinchieri, G., and Reed, S. G. A recombinant Leishmania antigen that stimulates human peripheral blood mononuclear cells to express a Th1-type cytokine profile and to produce interleukin 12. J. Exp. Med., 181: 1527-1537, 1995.
24. Widmer, M. B., Acres, R. B., Sassenfeld, H. M., and Grabstein, K. H. Regulation of cytolytic cell populations from human peripheral blood by B cell stimulatory factor 1 (interleukin 4). J. Exp. Med., 166: 1447-1455, 1987.
25. Golumbek, P. T., Lazenby, A. J., Levitsky, H. I., Jaffee, L. M., Karasuyama, H., Baker. M., and Pardoll, D. M. Treatment of established renal cancer by tumor cells engineered to secrete interleukin-4. Science (Washington DC), 254: 713-716, 1991.
26. Tepper, R. I., Coffman, R. L., and Leder, P. An eosinophil-dependent mechanism for the antitumor effect of interleukin-4 Science (Washington DC), 257: 548-551, 1992.
27. Berman, J. S., Cruikshank, W. W., Center, D. M., Theodore, A. C., and Beer, D. J. Chemoattractant lymphokines specific for the helper/inducer T-lymphocyte subset. Cell. Immunol., 95: 105-112, 1985.
28. + T cells in vitro. J. Immunol., 156: 310-315, 1996.
29. + double-negative cytotoxic T lymphocytes. Jpn. J. Cancer Res., 84: 58-64, 1993.